LQDA, US53635D2027

Liquidia schedules November 2 results. Liquidia stock costs EUR 40.77 after hours

Published on 10/27/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Liquidia expects USD 214.18 million revenue for Q3 2026 on November 2. Liquidia stock costs EUR 40.77 on October 27, 2026 at 9:45 p.m. CEST.

Reporting date November 2, 2026

Liquidia scheduled third-quarter 2026 results for November 2, 2026.
Analysts project USD 214.18 million in third-quarter 2026 revenue.
Liquidia stock costs EUR 40.77 at Lang & Schwarz on October 27, 2026 at 9:45 p.m. CEST.

LQDA, US53635D2027, Illustration mit AI erstellt.

Liquidia (ISIN US53635D2027) is scheduled to report third-quarter 2026 results before the market opens on November 2, 2026, with analysts projecting USD 214.18 million in revenue and USD 0.92 in earnings per share, according to MarketBeat. Liquidia stock was trading at EUR 40.77 at Lang & Schwarz on October 27, 2026 at 9:45 p.m. CEST.

November 2 puts revenue first

The upcoming report will test whether Liquidia can build on the USD 171.68 million revenue reported for the second quarter of 2026. That figure exceeded the USD 168.48 million consensus estimate, while revenue increased 1,842.10 percent from the same quarter a year earlier, according to MarketBeat.

The second-quarter earnings picture was less straightforward. Liquidia reported USD 0.74 in earnings per share for the quarter, below the USD 0.76 consensus estimate, even as revenue beat expectations.

Stock remains below its yearly high

Liquidia's USD 45.44 Nasdaq quote at 8:00 p.m. UTC on October 27, 2026 converts to 4:00 p.m. ET and stood below its USD 93.61 52-week high. The same quote showed a USD 22.05 52-week low, USD 4.1 billion market capitalization and 3,143,231 shares traded.

Analyst views remain divided

Bank of America analyst Jason Gerberry raised the price target to USD 42 from USD 38 and retained a Neutral rating on October 15, 2026, according to Markets Insider. Other recent research cited by MarketBeat included a USD 65 target from H.C. Wainwright and a USD 70 target from BTIG Research, both dated October 2026.

The November 2 release therefore matters for two reasons: it will provide a fresh revenue comparison and show whether earnings per share are moving closer to analyst expectations. Liquidia develops therapies for pulmonary hypertension and other serious cardiopulmonary diseases, with Yutrepia as its lead product.

Liquidia market details

Liquidia's next scheduled reporting date is November 2, 2026. Its primary listing is Nasdaq under ticker LQDA, and the company operates in biotechnology with a focus on pulmonary hypertension therapies.

Stock position and next date

Liquidia stock was trading at EUR 40.77 at Lang & Schwarz on October 27, 2026 at 9:45 p.m. CEST. The next scheduled event is the company's third-quarter 2026 results release before the market opens on November 2, 2026.

The further course of trading is shown by the continuously updated real-time quote of Liquidia stock.